Rare Disease Year in Review
This year has been a tumultuous year for the rare diseases market with a number of significant news stories revolving around M&A rumours, regulatory approvals, IPO’s, investments and partnering...
View ArticleUltragenyx focused on ultra-rare disease future
Authored by Paul Foster As part of Liftstream’s commitment to rare diseases, in the run up to Rare Disease Day 2013 we will be profiling 10 companies that are leading the rare disease research effort....
View ArticleSanofi Suffers Setback with two drugs
Authored by James Sheppard Sanofi suffered multiple failures as it chose to drop two drugs. Lung cancer drug iniparib and anticoagulant otamixaban both ceased development after negative phase III data....
View ArticlePharma marries VCs to give birth to Biotechs
Authored by Karl Simpson A marriage made of true love or one of convenience. Whichever, these consummations between pharma and venture capitalists are increasingly frequent and in recent weeks we’ve...
View ArticleMassachusetts biotech continues to excite with new investments
Authored by Karl Simpson Massachusetts is a booming biotech cluster and this week has seen a number of funding events that once again signal the level of innovation and investor interest the cluster...
View ArticleAcademic and industry partnerships drive new Gene Therapy push
Authored by James Sheppard There are many areas of pharmaceutical innovation currently receiving considerable attention, both for their scientific potential in a personalised medicine era but equally...
View ArticleOsiris sells stem cell business in $100m deal
Authored by James Sheppard The US based biotechnology company Osiris Therapeutics has announced a $100m deal with Australian biotech Mesoblast for the company to buy its stem cell platform. The deal...
View ArticleSanofi appoint Chief Patient Officer
Authored by James Sheppard The French pharmaceutical giant Sanofi recently announced that it had appointed Dr Anne C. Beal as its new Chief Patient Officer. This is a new role within Sanofi and one...
View ArticleExecutive Recruitment Round-up October 2014
Authored by James Sheppard Atlas ventures appointed Jason Rhodes as a Partner in its life sciences team. Jason arrives at Atlas from Epizyme where he was President and Chief Financial Officer (CFO). At...
View Article
More Pages to Explore .....